On May 7, the Food and Drug Administration (FDA) Commissioner Robert Califf called on Congress to collaborate with the FDA to create a better regulatory pathway for cannabis products. The Commissioner underscored the need for systematic regulation to ensure harm reduction, citing safety concerns with ingestible cannabinoid products like Delta-8 THC gummies.
This call aligns with the United States Senate’s recent reintroduction of the Cannabis Administration and Opportunity Act, which proposes removing cannabis from the federal Controlled Substances Act and establishing a Center for Cannabis Products within the FDA. The bill would set standards for cannabis product manufacturing, labeling, and distribution. Additionally, on May 16, the Department of Justice also issued a proposed rule that would reschedule marijuana from Schedule I to Schedule III, facilitating broader medical use and research.
For more information about the need to create a regulatory framework for consumer products containing CBD that are intended for human ingestion, view Aimed Alliances’ resources: Essential Labeling Requirements for Consumer Products Containing Cannabis-Derived Ingredients and Intended for Human Ingestion & Essential Elements of a Regulatory Framework for Consumer Products Containing Cannabis-Derived Ingredients and Intended for Human Ingestion.
Last Updated on May 21, 2024 by Aimed Alliance
